NASHVILLE, Tenn., July 30,
2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
(Nasdaq: CPIX), a specialty pharmaceutical company, announced today
that it will release its second quarter 2024 financial results and
provide a company update after the market closes on Tuesday, Aug. 6, 2024.
A conference call will be held on Aug.
6 at 4:30 p.m. Eastern Time to
discuss the results. To participate in the call, please register at
https://register.vevent.com/register/BIfa6a94515e5548c28e9d77d03c95a13e.
Once registered, participants can dial in from their phone using
a dial-in and PIN number that will be provided to them.
Alternatively, they can choose a "Call Me" option to have the
system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be
accessed via Cumberland's website
or by visiting https://edge.media-server.com/mmc/p/h9bx4zn8.
Cumberland Pharmaceuticals is a specialty pharmaceutical company
focused on providing unique products that improve patient
care. The company develops, acquires, and commercializes products
for the hospital acute care, gastroenterology and oncology market
segments.
The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection,
for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for
the treatment of pain and fever;
- Kristalose® (lactulose) for oral
solution, a prescription laxative, for the treatment of
constipation;
- Omeclamox®-Pak, (omeprazole,
clarithromycin, amoxicillin) for the treatment of Helicobacter
pylori (H. pylori) infection and related duodenal ulcer
disease;
- Sancuso® (granisetron) transdermal
system, for the prevention of nausea and vomiting in patients
receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to
raise serum sodium levels in hospitalized patients with euvolemic
and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for
the treatment of certain serious bacterial infections including
hospital-acquired and ventilator-associated bacterial pneumonia, as
well as complicated skin and skin structure infections.
The company also has a series of Phase II clinical programs
underway evaluating its ifetroban product candidate in patients
with cardiomyopathy associated with Duchenne Muscular Dystrophy and
Systemic Sclerosis. Additionally, Cumberland recently received FDA clearance to
proceed directly to a Phase II study for patients with Idiopathic
Pulmonary Fibrosis, the most common form of progressive fibrosing
interstitial lung disease.
For more information on Cumberland's approved products, including full
prescribing information, please visit links to the individual
product websites, which can be found on the company's website at
www.cumberlandpharma.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-second-quarter-2024-financial-results-302210213.html
SOURCE Cumberland Pharmaceuticals
